
News|Articles|November 1, 2005
Safety Labeling updates and new warnings
The manufacturer of ato-moxetine (Strattera, Lilly) was directed by FDA to revise the prescribing information for the drug to include a black box warning and additional statements that alert healthcare providers of an increased risk of suicidal thinking in children and adolescents being treated with this medication.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
2
Myqorzo is now available for rare heart condition at a $108,400 annual price
3
Could GLP-1s help with cognitive symptoms, pychosis of schizophrenia?
4
When it comes to quality measures, fewer is viewed as better, says Ben Shirley of PQA | Part 2
5























